Preview

Медицинский Совет

Расширенный поиск

Место омализумаба в терапии аллергических заболеваний

https://doi.org/10.21518/2079-701X-2019-15-38-49

Полный текст:

Аннотация

В статье описан современный подход к применению антиIgE-терапии при аллергической бронхиальной астме и сопутствующих этому заболеванию состояниях. Гуманизированное моноклональное антитело против IgE, препарат омализумаб (Ксолар®) – это перспективный способ лечения IgE-опосредованных аллергических заболеваний. Получены многочисленные доказательства эффективности омализумаба при аллергической бронхиальной астме и хронической спонтанной (идиопатической) крапивнице, на основании которых проведены глобальные метаанализы, подтвердившие эффективность и безопасность этой терапевтической стратегии. В последних научных статьях активно обсуждается возможность расширения показаний для медицинского применения омализумаба. Опубликованы результаты клинических исследований эффективности и безопасности использования омализумаба при аллергическом рините, аллергическом кератоконъюнктивите, хроническом риносинусите, назальных полипах, хронической идиопатической крапивнице, пищевой аллергии, при аллергенспецифической иммунотерапии, атопическом дерматите, аллергическом бронхолегочном аспергиллезе – в случаях коморбидности с бронхиальной астмой. Наиболее изучен и доказан клинический эффект омализумаба у пациентов с аллергической бронхиальной астмой. В настоящий момент ряд клинических исследований оценивают отдаленные результаты длительного применения омализумаба или состояние после его отмены у пациентов с аллергической бронхиальной астмой и различными коморбидностями.

Об авторах

О. М. Курбачёва
Государственный научный центр «Институт иммунологии» Федерального медико-биологического агентства
Россия

д.м.н., профессор, заведующая отделением «Бронхиальная астма» клиники,

115478, Москва, Каширское шоссе, д. 24



М. А. Галицкая
Государственный научный центр «Институт иммунологии» Федерального медико-биологического агентства
Россия

аспирант, младший научный сотрудник,

115478, Москва, Каширское шоссе, д. 24



Список литературы

1. Warner J.O., Kaliner M.A., Crisci C.D., Del Giacco S., Frew A.J., Liu G.H., et al. Allergy practice worldwide: a report by the World Allergy Organization Specialty and Training Council. Int Arch Allergy Immunol. 2006;139:166–74. doi: 10.1159/000090502.

2. Weinberg E.G. The WAO white book on allergy 2011-2012: review article. Curr Allergy Clin Immunol. 2011;24(3):156–7.

3. Pawankar R.C.G., Holgate S.T. World allergy organization (WAO) white book on allergy. Update. 2013;248. doi: 10.1186/1939-4551-6-3.

4. Nitin J., Palagani R., Shradha N.H., Vaibhav J., Kowshik K., Manoharan R., et al. Prevalence, severity and risk factors of allergic disorders among people in south India. Afr Health Sci. 2016;16:201–209. doi: 10.4314/ahs.v16i1.27.

5. Hannah J., Gould H.J., Sutton B.J. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8:205-217. doi: 10.1038/nri2273.

6. Siracusa M.C., Kim B.S., Spergel J.M., Artis D. Basophils and allergic inflammation. J Allergy Clin Immunol. 2013;132:789-801. doi: 10.1016/j.jaci.2013.07.046.

7. Cameron L., Christodoulopoulos P., Lavigne F., Nakamura Y., Eidelman D., McEuen A., et al. Evidence for local eosinophil differentiation within allergic nasal mucosa: inhibition with soluble IL-5 receptor. J Immunol. 2000;164:1538-1545. doi: 10.4049/jimmunol.164.3.1538.

8. Muramatsu M., Kinoshita K., Fagarasan S., Yamada S., Shinkai Y., Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102:553-563. doi: 10.1016/s0092-8674(00)00078-7.

9. Pène J., Rousset F., Brière F., Chrétien I., Bonnefoy J.Y., Spits H., et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc Natl Acad Sci U S A. 1988;85:6880-6884. doi: 10.1073/pnas.85.18.6880.

10. Luger E.O., Fokuhl V., Wegmann M., Abram M., Tillack K., Achatz G., et al. Induction of longlived allergen-specific plasma cells by mucosal allergen challenge. J Allergy Clin Immunol. 2009;124:819-826.e4. doi: 10.1016/j.jaci.2009.06.047.

11. Erazo A., Kutchukhidze N., Leung M., Christ A.P., Urban J.F. Jr, Curotto de Lafaille M.A., et al. Unique maturation program of the IgE response in vivo. Immunity. 2007;26:191-203. doi: 10.1016/j.immuni.2006.12.006.

12. Suh K.S., Park H.S., Nahm D.H., Kim Y.K., Lee Y.M., Park K. Role of IgG, IgA, and IgE antibodies in nasal polyp tissue: their relationships with eosinophilic infiltration and degranulation. J Korean Med Sci. 2002;17:375-380. doi: 10.3346/jkms.2002.17.3.375.

13. Sheahan P., Ahn C.N., Harvey R.J., Wise S.K., Mulligan R.M., Lathers D.M., et al. Local IgE production in nonatopic nasal polyposis. J Otolaryngol Head Neck Surg. 2010;39(1):45-51. Available at: https://europepmc.org/abstract/med/20122344.

14. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151(5):2623– 2632. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8360482.

15. Corren J., Busse W., Meltzer E.O., Mansfield L., Bensch G., Fahrenholz J., et al. A randomized, controlled, phase 2 study of AMG 317, an IL4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med. 2010;181:788-96. doi: 10.1164/rccm.200909-1448oc.

16. Incorvaia C., Mauro M., Riario-Sforza G.G., Frati F., Tarantini F., Caserini M. Current and future applications of the anti-IgE antibody omalizumab. Biologics. 2008;2(1):67–73. doi: 10.2147/btt.s1800.

17. Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455-66. doi: 10.1056/nejmoa1304048.

18. Kimura S., Pawankar R., Mori S., Nonaka M., Masuno S., Yagi T., et al. Increased expression and role of thymic stromal lymphopoietin in nasal polyposis. Allergy Asthma Immunol Res. 2011;3:186-93. doi: 10.4168/aair.2011.3.3.186.

19. Gauvreau G.M., O’Byrne P.M., Boulet L.P., Wang Y., Cockcroft D., Bigler J., et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102-2110. doi: 10.1056/nejmoa1402895.

20. Zheng L., Li B., Qian W., Zhao L., Cao Z., Shi S., et al. Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab. Biochem Biophys Res Commun. 2008;375:619–622. doi: 10.1016/j.bbrc.2008.08.055.

21. Eggel A., Baravalle G., Hobi G., Kim B., Buschor P., Forrer P., et al. Accelerated dissociation of IgE-FcepsilonRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J Allergy Clin Immunol. 2014;133:1709–19 e1708. doi: 10.1016/j.jaci.2014.02.005.

22. Chang T.W., Wu P.C., Hsu C.L., Hung A.F. AntiIgE antibodies for the treatment of IgEmediated allergic diseases. Adv Immunol. 2007;93:63–119. doi: 10.1016/s0065-2776(06)93002-8.

23. Holgate S., Bousquet J., Wenzel S., Fox H., Liu J., Castellsague J. Efficacy of omalizumab, all anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthmarelated morbidity and mortality. Curt Med Res Opin. 2001;17(4):233–40. doi: 10.1185/030079901753403126.

24. Zhou B., Lin B., Li J., Qian W., Hou S., Zhang D., et al. Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects. mAbs. 2012;4:110–19. doi: 10.4161/mabs.4.1.18349.

25. Kawakami T., Blank U. From IgE to omalizumab. J Immunol. 2016;197:4187–4192. doi: 10.4049/jimmunol.1601476.

26. Tonacci A., Billeci L., Pioggia G., Navarra M., Gangemi S. Omalizumab for the treatment of chronic idiopathic urticaria: systematic review of the literature. Pharmacotherapy. 2017;37:464–480. doi: 10.1002/phar.1915.

27. Lustgarten J., Eshhar Z. Specific elimination of Ige production using T-cell lines expressing chimeric T-cell receptor genes. Eur J Immunol. 1995;25:2985–2991. doi: 10.1002/eji.1830251041.

28. Jardieu P.M., Fick R.B. IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol. 1999;118(2–4):112–115. doi: 10.1159/000024043.

29. Holgate S., Casale T., Wenzel S., Bousquet J., Deniz Y., Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459-465. doi: 10.1016/j.jaci.2004.11.053.

30. Cox L., Platts-Mills T.A., Finegold I., et al; American Academy of Allergy, Asthma & Immunology; American College of Allergy, Asthma and Immunology. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120(6):1373–1377. doi: 10.1016/j.jaci.2007.09.032.

31. Nopp A., Johansson S.G., Adédoyin J., Ankerst J., Palmqvist M., Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy. 2010;65(1):56–60. doi: 10.1111/j.1398-9995.2009.02144.x.

32. Ledford D., Busse W., Trzaskoma B., et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162– 169.e2. doi: 10.1016/j.jaci.2016.08.054.

33. Domingo C., Pomares X., Navarro A., et al. A step-down protocol for treatment in oral corticosteroid dependent allergic asthma patients. Br J Clin Pharmacol. 2018;84(2):339– 348. doi: 10.1111/bcp.13453.

34. Vennera Mdel C., Valero A., Uria E., Forne C., Picado C. Cost-effectiveness analysis of omalizumab for the treatment of severe persistent asthma in real clinical practice in Spain. Clin Drug Investig. 2016;36(7):567–578. doi: 10.1007/s40261-016-0402-2.

35. Suzuki C., Lopes da Silva N., Kumar P., Pathak P., Ong S.H. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. J Med Econ. 2017;20(8):832–839. doi: 10.1080/13696998.2017.1333513.

36. Zafari Z., Sadatsafavi M., Mark FitzGerald J.; Canadian Respiratory Research Network. Canadian Respiratory Research Network. Costeffectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. Cost Eff Resour Alloc. 2018;30:16–3. doi: 10.1186/s12962-018-0089-8.

37. Global Initiative for Asthma Report, Global strategy for Asthma Management and Prevention. Available at: https://ginasthma. org/2018-gina-report-global-strategy-forasthma-management-and-prevention/ Accessed May 13, 2018.

38. Zafari Z., Sadatsafavi M., Marra C.A., Chen W., FitzGerald J.M. Cost-Effectiveness of bronchial thermoplasty, omalizumab, and standard therapy for moderate-to-severe allergic asthma. PLoS One. 2016;11(1):e0146003. doi: 10.1371/journal.pone.0146003.

39. Tatar M., Sezen S., Senturk A., Balp M.M., Saylan M., Keskinaslan A. Costeffectiveness of omalizumab in chronic idiopathic urticarial refractory to H1-antihistamines in Turkey. Value Health. 2014;17(7):A604. doi: 10.1016/j.jval.2014.08.2101.

40. Alhossan A., Lee C.S., MacDonald K., Abraham I. «Real-life» Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362–1370.e2. doi: 10.1016/j.jaip.2017.02.002.

41. Lai T., Wang S., Xu Z. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015;3(5):8191. doi: 10.1038/srep08191.

42. Walker S., Monteil M., Phelan K., Lasserson T.J., Walters E.H. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006;19(2):CD003559. doi: 10.1002/14651858.cd003559.pub3.

43. Siergiejko Z., Świebocka E., Smith N., et al. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin. 2011;27(11):2223–2228. doi: 10.1185/03007995.2011.620950.

44. Domingo C., Moreno A., Jose Amengual M., Montуn C., Suбrez D., Pomares X. Omalizumab in the management of oral corticosteroiddependent IGE-mediated asthma patients. Curr Med Res Opin. 2011;27(1):45–53. doi: 10.1185/03007995.2010.536208.

45. Barnes N., Menzies-Gow A., Mansur A.H., et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma. 2013;50(5):529–536. doi: 10.3109/02770903.2013.790419.

46. Braunstahl G.J., Chen C.W., Maykut R., Georgiou P., Peachey G., Bruce J. The eXpeRience registry: the «real-world» effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141–1151. doi: 10.1016/j.rmed.2013.04.017.

47. Normansell R., Walker S., Milan S.J., Walters E.H., Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):CD003559. doi: 10.1002/14651858. cd003559.pub4.

48. Cardet J.C., Casale Т.В. New insights into the utility of omalizumab. J Allergy Clin Immunol. 2019;143(3):923-936. doi: 10.1016/j.jaci.2019.01.016.

49. Zhao Z.-T. et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742-1750. doi: 10.1016/j.jaci.2015.12.1342.

50. Tharp M.D. et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of «realworld» evidence. JAMA dermatology. 2019;155(1):29-38. doi: 10.1001/jamadermatol.2018.3447.

51. Marzano A.V., Genovese G., Casazza G., Fierro M.T., Dapavo P., Crimi N., et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. J Eur Acad Dermatol Venereol. 2018;33(5):918-924. doi: 10.1111/jdv.15350.

52. Asero R., Marzano A.V., Ferrucci S., Cugno M. Elevated baseline D-dimer plasma levels are associated with a prompt response to omalizumab in patients with severe CSU. J Allergy Clin Immunol Pract. 2017;5:1740-1742. doi: 10.1016/j.jaip.2017.07.009.

53. Maurer M., Metz M., Brehler R., Hillen U., Jakob T., Mahler V., et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018;141:638- 49. doi: 10.1016/j.jaci.2017.06.032.

54. Gericke J., Metz M., Ohanyan T., Weller K., Altrichter S., Skov P.S., et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;139:1059-61.e1. DOI: 10.1016/j.jaci.2016.07.047

55. Zuberbier T., Aberer W., Asero R., et al. The EAACI/GA2LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. Allergy. 2018;73(7):1393-1414. doi: 10.1111/all.13397.

56. Pawankar R., Mori S., Ozu C., Kimura S. Overview on the pathomechanisms of allergic rhinitis. Asia Pac Allergy. 2011;1:157-67. doi: 10.5415/apallergy.2011.1.3.157.

57. Phillips K.M., Hoehle L.P., Caradonna D.S., Gray S.T., Sedaghat A.R. Association of severity of chronic rhinosinusitis with degree of comorbid asthma control. Ann Allergy Asthma Immunol. 2016;117:651-654. doi: 10.1016/j.anai.2016.09.439.

58. Leynaert B., Neukirch F., Demoly P., Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol. 2000;106:S201-5. doi: 10.1067/mai.2000.110151.

59. Asher M.I., Montefort S., Björkstén B., Lai C.K., Strachan D.P., Weiland S.K., et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733-743. doi: 10.1016/s0140-6736(06)69283-0.

60. Bousquet J., Vignola A.M., Demoly P. Links between rhinitis and asthma. Allergy. 2003;58:691-706. doi: 10.1034/j.1398-9995.2003.00105.x.

61. Simons F.E. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol. 1999;104:534-540. doi: 10.1016/s0091-6749(99)70320-9.

62. Vignola A.M., Chanez P., Godard P., Bousquet J. Relationships between rhinitis and asthma. Allergy. 1998;53:833-839. doi: 10.1111/j.1398-9995.1998.tb03988.x.

63. Ziyab A.H. Prevalence and risk factors of asthma, rhinitis, and eczema and their multimorbidity among young adults in Kuwait: a cross-sectional study. Biomed Res Int. 2017;2017:1-10. doi: 10.1155/2017/2184193.

64. Grossman J. One airway, one disease. Chest. 1997;111:11S-6S. doi: 10.1378/chest.111.2_ supplement.11s.

65. Brito Rde C., da Silva G.A., Motta M.E., Brito M.C. The association of rhinoconjunctivitis and asthma symptoms in adolescents. Rev Port Pneumol. 2009;15:613-28. doi: 10.1016/s2173-5115(09)70137-x.

66. Adelroth E., Rak S., Haahtela T., Aasand G., Rosenhall L., Zetterstrom O., et al. Recombinant humanized mAb-E25, an antiIgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106:253-259. doi: 10.1067/mai.2000.108310.

67. Casale T.B., Condemi J., LaForce C., Nayak A., Rowe M., Watrous M., et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001;286:2956-2967. doi: 10.1001/jama.286.23.2956.

68. Vignola A.M., Humbert M., Bousquet J., Boulet L.P., Hedgecock S., Blogg M., et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59:709- 717. doi: 10.1111/j.1398-9995.2004.00550.x.

69. Tabbara K.F. Ocular complications of vernal keratoconjunctivitis. Can J Ophthalmol. 1999;34:88-92. Available at: https://www. ncbi.nlm.nih.gov/pubmed/10321319.

70. Vichyanond P., Pacharn P., Pleyer U., Leonardi A. Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes. Pediatr Allergy Immunol. 2014;25:314-22. doi: 10.1111/pai.12197.

71. Bonini S., Bonini S., Lambiase A., Marchi S., Pasqualetti P., Zuccaro O., et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with longterm follow-up. Ophthalmology. 2000;107:1157-63. doi: 10.1016/s0161-6420(00)00092-0.

72. Sánchez J., Cardona R. Omalizumab. An option in vernal keratoconjunctivitis? Allergol Immunopathol (Madr). 2012;40:319-20. doi: 10.1016/j.aller.2011.08.002.

73. de Klerk T.A., Sharma V., Arkwright P.D., Biswas S. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. J AAPOS. 2013;17:305-6. doi: 10.1016/j.jaapos.2012.12.153.

74. Doan S., Amat F., Gabison E., Saf S., Cochereau I., Just J. Omalizumab in severe refractory vernal keratoconjunctivitis in children: case series and review of the literature. Ophthalmol Ther. 2017;6:195-206. doi: 10.1007/s40123-016-0074-2.

75. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50:1-12. doi: 10.4193/rhino50e2.

76. Bachert C., Zhang L., Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136:1431-1440. doi: 10.1016/j.jaci.2015.10.010.

77. Tomassen P., Vandeplas G., Van Zele T., Cardell L.O., Arebro J., Olze H., et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137:1449-1456.e4. doi: 10.1016/j.jaci.2015.12.1324.

78. Bantz S.K., Zhu Z., Zheng T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol. 2014;5:202. doi: 10.4172/2155- 9899.1000202.

79. Jarvis D., Newson R., Lotvall J., Hastan D., Tomassen P., Keil T., et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2012;67:91-8. doi: 10.1111/j.1398-9995.2011.02709.x.

80. Bachert C., Gevaert P., Holtappels G., Johansson S.G., van Cauwenberge P. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol. 2001;107:607-614. doi: 10.1067/mai.2001.112374.

81. Kang J.W., Nahm D.H., Suh K.S., Kim H.Y., Park H.S. Local production of specific IgE antibody to house dust mite in nasal polyp tissues. J Asthma Allergy Clin Immunol. 1998;18:426-433.

82. Ying S., Humbert M., Meng Q., Pfister R., Menz G., Gould H.J., et al. Local expression of epsilon germline gene transcripts and RNA for the epsilon heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. J Allergy Clin Immunol. 2001;107:686-692. doi: 10.1067/mai.2001.114339.

83. Zhang N., Holtappels G., Gevaert P., Patou J., Dhaliwal B., Gould H., et al. Mucosal tissue polyclonal IgE is functional in response to allergen and SEB. Allergy. 2011;66:141-148. doi: 10.1111/j.1398-9995.2010.02448.x.

84. Van Zele T., Gevaert P., Holtappels G., Beule A., Wormald P.J., Mayr S., et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125:1069-1076.e4. doi: 10.1016/j.jaci.2010.02.020.

85. Gevaert P., Calus L., Van Zele T., Blomme K., De Ruyck N., Bauters W., et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131:110-116.e1. doi: 10.1016/j.jaci.2012.07.047.

86. Penn R., Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol. 2007;21:428-432. doi: 10.2500/ajr.2007.21.3060.

87. Vennera Mdel C., Picado C., Mullol J., Alobid I., Bernal-Sprekelsen M. Efficacy of omalizumab in the treatment of nasal polyps. Thorax. 2011;66:824-825. doi: 10.1136/thx.2010.152835.

88. Gevaert P., Calus L., Van Zele T., Blomme K., De Ruyck N., Bauters W., et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131:110-116.e1. doi: 10.1016/j.jaci.2012.07.047.

89. Pinto J.M., Mehta N., DiTineo M., Wang J., Baroody F.M., Naclerio R.M. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48:318-324. doi: 10.4193/rhin09.144.

90. Garcia G., Magnan A., Chiron R., et al. A proofof-concept, randomized, controlled trial of omalizumab in patients with severe, difficulttocontrol, nonatopic asthma. Chest. 2013;144(2):411–419. doi: 10.1378/chest.12-1961.

91. Domingo C., Pomares X., Angril N., Rudi N., Amengual M.J., Mirapeix R.M. Effectiveness of omalizumab in non-allergic severe asthma. J Biol Regul Homeost Agents. 2013;27(1):45–53.

92. Bousquet J., Lockey R., Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102(4 Pt 1):558– 562. doi: 10.1016/s0091-6749(98)70271-4.

93. James C., Bernstein D.I. Allergen immunotherapy: an updated review of safety. Curr Opin Allergy Clin Immunol. 2017;17(1):55–59. doi: 10.1097/aci.0000000000000335.

94. Normansell R., Kew K.M., Bridgman A.L. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2015;(8):CD011293. doi: 10.1002/14651858. cd011293.pub2.

95. Lambert N., Guiddir T., Amat F., Just J. Pretreatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma. Pediatr Allergy Immunol. 2014;25(8):829–832. doi: 10.1111/ pai.12306.

96. Casale T.B., Busse W.W., Kline J.N., et al; Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117(1):134–140. doi: 10.1016/j.jaci.2005.09.036.

97. Massanari M., Nelson H., Casale T., et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125(2):383–389. doi: 10.1016/j. jaci.2009.11.022.

98. Dantzer J.A., Wood R.A. The use of omalizumab in allergen immunotherapy. Clin Exp Allergy. 2018;48(3):232–240. doi: 10.1111/ cea.13084.

99. Incorvaia C., Mauro M., Gritti B.L., Makri E., Ridolo E. Venom immunotherapy in patients with allergic reactions to insect stings. Expert Rev Clin Immunol. 2018;14(1):53–59. doi: 10.1080/1744666x.2018.1413350.

100. Boni E., Incorvaia C., Mauro M. Dosedependence of protection from systemic reactions to venom immunotherapy by omalizumab. Clin Mol Allergy. 2016;14:14. doi: 10.1186/s12948-016-0051-2.

101. Abdel-Gadir A., Schneider L., Casini A., et al. Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy. 2018;48(7):825–836. doi: 10.1111/cea.13161.

102. Ильина Н.И., Курбачева О.М., Павлова К.С. Эффективность аллергенспецифической иммунотерапии на фоне приема препарата Омализумаб у пациентов с атопическими заболеваниями. Вопросы современной педиатрии. 2008;7(3):44-51. Режим доступа: https://vsp.spr-journal.ru/jour/article/view/1397.

103. Ильина Н.И., Курбачева О.М., Павлова К.С. Возможности комбинированного применения аллерген-специфической иммунотерапии с параллельным введением антиIgE-антител в лечении пациентов с атопическими заболеваниями. Российский аллергологический журнал. 2008;2:17-27. Режим доступа: http://rusalljournal.ru/journal/pdf/2008/2008-2/2-2008.pdf.

104. Shah A., Panjabi C. Allergic bronchopulmonary aspergillosis: a perplexing clinical entity. Allergy Asthma Immunol Res. 2016;8:282- 97. doi: 10.4168/aair.2016.8.4.282.

105. Agarwal R., Chakrabarti A., Shah A., Gupta D., Meis J.F., Guleria R., et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43:850-873. doi: 10.1111/cea.12141.

106. Agarwal R., Aggarwal A.N., Gupta D., Jindal S.K. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2009;13:936-944.

107. Hoyt A.E., Borish L., Gurrola J., Payne S. Allergic fungal rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4:599-604. doi: 10.1016/j.jaip.2016.03.010.

108. Humbert M., Bousquet J., Bachert C., Palomares O., Pfister P., Kottakis I., Jaumont X., Thomsen S.F., Papadopoulos N.G. IgEMediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. J Allergy Clin Immunol Pract. 2019;7(5):1418- 1429. doi: 10.1016/j.jaip.2019.02.030.

109. Eigenmann P.A., Beyer K., Wesley Burks A., et al. New visions for food allergy: an iPAC summary and future trends. Pediatr Allergy Immunol. 2008;19(19):26-39. doi: 10.1111/j.1399-3038.2008.00765.x.

110. Sicherer S.H. Food allergy. Mt Sinai J Med. 2011;78:683-696. doi: 10.1002/msj.20292.

111. Sicherer S.H., Sampson H.A. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol. 2014;133:291-307; quiz 8. doi: 10.1016/j.jaci.2013.11.020.

112. Tordesillas L., Berin M.C., Sampson H.A. Immunology of food allergy. Immunity. 2017;47:32-50. doi: 10.1016/j.immuni.2017.07.004.

113. Mills E.N., Mackie A.R., Burney P., Beyer K., Frewer L., Madsen C., et al. The prevalence, cost and basis of food allergy across Europe. Allergy. 2007;62:717-722. doi: 10.1111/j.1398-9995.2007.01425.x.

114. Wang J., Liu A.H. Food allergies and asthma. Curr Opin Allergy Clin Immunol. 2011;11:249- 254. doi: 10.1097/aci.0b013e3283464c8e.

115. Begin P., Chinthrajah R.S., Nadeau K.C. Oral immunotherapy for the treatment of food allergy. Hum Vaccin Immunother. 2014;10:2295-2302. doi: 10.4161/hv.29233.

116. Nadeau K.C., Kohli A., Iyengar S., DeKruyff R.H., Umetsu D.T. Oral immunotherapy and anti-IgE antibody-adjunctive treatment for food allergy. Immunol Allergy Clin North Am. 2012;32:111-133. doi: 10.1016/j.iac.2011.11.004.

117. Umetsu D.T, Rachid R., Schneider L.C. Oral immunotherapy and anti-IgE antibody treatment for food allergy. World Allergy Organ J. 2015;8:20. doi: 10.1186/s40413-015-0070-3.

118. Andorf S., Purington N., Block W.M., Long A.J., Tupa D., Brittain E., et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3:85-94. doi: 10.1016/s2468-1253(17)30392-8.

119. Labrosse R., Graham F., Des Roches A., Begin P. The use of omalizumab in food oral immunotherapy. Arch Immunol Ther Exp (Warsz). 2017;65:189-99. doi: 10.1007/s00005-016-0420-z.

120. Frischmeyer-Guerrerio P.A., Masilamani M., Gu W., Brittain E., Wood R., Kim J., et al. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2017;140:1043-1053.e8. doi: 10.1016/j.jaci.2017.03.028.

121. Savage J.H., Courneya J.P., Sterba P.M., Macglashan D.W., Saini S.S., Wood R.A. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol. 2012;130:1123-1129.e2. doi: 10.1016/j.jaci.2012.05.039.

122. Rafi A., Do L.T., Katz R., Sheinkopf L.E., Simons C.W., Klaustermeyer W. Effects of omalizumab in patients with food allergy. Allergy Asthma Proc. 2010;31:76-83. doi: 10.2500/aap.2010.31.3304.

123. Sampson H.A., Leung D.Y., Burks A.W., Lack G., Bahna S.L., Jones S.M., et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127:1309-13010. e1. doi: 10.1016/j.jaci.2011.01.051.

124. Leung D.Y., Sampson H.A., Yunginger J.W., Burks A.W. Jr, Schneider L.C., Wortel C.H., et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348:986- 993. doi: 10.1056/nejmoa022613.

125. Galli E., Gianni S., Auricchio G., Brunetti E., Mancino G., Rossi P. Atopic dermatitis and asthma. Allergy Asthma Proc. 2007;28:540-3. doi: 10.2500/aap2007.28.3048.

126. Eichenfield L.F., Hanifin J.M., Beck L.A., Lemanske R.F. Jr, Sampson H.A., Weiss S.T., et al. Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics. 2003;111:608-616. doi: 10.1542/peds.111.3.608.

127. van der Hulst A.E., Klip H., Brand P.L. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol. 2007;120:565-569. doi: 10.1016/j.jaci.2007.05.042.

128. Celakovská J., Buka C.J. The severity of atopic dermatitis evaluated with the SCORAD index and the occurrence of bronchial asthma and rhinitis, and the duration of atopic dermatitis. Allergy Rhinol (Providence). 2016;7:8-13. doi: 10.2500/ar.2016.7.0144.

129. Iyengar S.R., Hoyte E.G., Loza A., Bonaccorso S., Chiang D., Umetsu D.T., et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 2013;162:89-93. doi: 10.1159/000350486.

130. Heil P.M., Maurer D., Klein B., Hultsch T., Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebocontrolled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8:990-998. DOI: 10.1111/j.1610-0387.2010.07497.x.

131. Holm J.G., Agner T., Sand C., Thomsen S.F. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. Int J Dermatol. 2017;56:18-26. doi: 10.1111/ijd.13353.

132. Chan S., Cornelius V., Chen T., Radulovic S., Wan M., Jahan R., et al. Atopic Dermatitis AntiIgE Paediatric Trial (ADAPT): the role of antiIgE in severe paediatric eczema: study protocol for a randomised controlled trial. Trials. 2017;18:136. doi: 10.1186/s13063-017-1809-7.

133. Sheinkopf L.E., Rafi A.W., Do L.T., Katz R.M., Klaustermeyer W.B. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc. 2008;29:530-537. doi: 10.2500/aap.2008.29.3160.


Для цитирования:


Курбачёва О.М., Галицкая М.А. Место омализумаба в терапии аллергических заболеваний. Медицинский Совет. 2019;(15):38-49. https://doi.org/10.21518/2079-701X-2019-15-38-49

For citation:


Kurbacheva O.M., Galitskaya M.A. The place of Omalizumab in the treatment of allergic diseases. Meditsinskiy sovet = Medical Council. 2019;(15):38-49. (In Russ.) https://doi.org/10.21518/2079-701X-2019-15-38-49

Просмотров: 208


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)